Rachel K. King Sells 4,150 Shares of Novavax, Inc. (NASDAQ:NVAX) Stock

Novavax, Inc. (NASDAQ:NVAX) Director Rachel K. King sold 4,150 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the sale, the director now directly owns 14,770 shares of the company’s stock, valued at $133,225.40. This represents a 21.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Novavax Price Performance

NASDAQ:NVAX traded up $0.53 during mid-day trading on Thursday, reaching $8.57. 3,813,721 shares of the company’s stock traded hands, compared to its average volume of 9,060,255. The company has a 50 day moving average price of $8.74 and a 200-day moving average price of $11.40. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -3.79 and a beta of 2.02. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $23.86.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.07. The firm had revenue of $84.51 million during the quarter, compared to analysts’ expectations of $65.80 million. Novavax’s revenue for the quarter was down 54.8% on a year-over-year basis. During the same period in the previous year, the company earned ($1.26) earnings per share. As a group, analysts forecast that Novavax, Inc. will post -1.44 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on NVAX shares. Jefferies Financial Group decreased their price target on Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, October 16th. HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price on shares of Novavax in a research report on Tuesday, December 10th. Finally, B. Riley reissued a “buy” rating and issued a $26.00 price target (up from $23.00) on shares of Novavax in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $17.83.

Hedge Funds Weigh In On Novavax

Several hedge funds and other institutional investors have recently modified their holdings of NVAX. Charles Schwab Investment Management Inc. grew its holdings in Novavax by 16.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,325,508 shares of the biopharmaceutical company’s stock valued at $16,741,000 after purchasing an additional 187,548 shares during the period. Bank of Montreal Can grew its position in shares of Novavax by 26.7% during the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock valued at $32,643,000 after purchasing an additional 517,727 shares in the last quarter. Shah Capital Management increased its stake in Novavax by 19.0% in the 2nd quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company’s stock worth $122,322,000 after acquiring an additional 1,544,263 shares during the last quarter. State Street Corp raised its stake in Novavax by 26.7% during the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock valued at $97,099,000 after purchasing an additional 1,621,772 shares in the last quarter. Finally, Vontobel Holding Ltd. lifted its holdings in shares of Novavax by 110.3% in the 3rd quarter. Vontobel Holding Ltd. now owns 498,532 shares of the biopharmaceutical company’s stock valued at $6,296,000 after acquiring an additional 261,464 shares during the last quarter. 53.04% of the stock is owned by institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.